Shreehas P Tambe
Chief Executive Officer and Managing Director, Biocon
Shreehas Tambe is the CEO & Managing Director of the combined generics and biosimilars business at Biocon Limited.
Across nearly three decades with Biocon, Shreehas has held several leadership roles, playing a pivotal part in scaling multiple businesses globally and advancing science-led access to life‑changing medicines for patients worldwide.
During his tenure as the CEO & Managing Director of Biocon Biologics, the company has become one of the world’s Top 5 biosimilar companies by revenue with a valuation of USD 5.5 billion in 2025. He led the transformational acquisition of Viatris’ biosimilars business and oversaw its rapid consolidation, creating a fully integrated, lab-to-patient, global biologics enterprise.
Before taking on the helm at Biocon Biologics, Shreehas served as Chief Operating Officer and later as Deputy CEO, overseeing enterprise-wide operations and global growth agenda.
In an earlier mandate at Biocon, he led the worldwide expansion of the insulins business, directing end-to-end development, manufacturing, and market entry strategies, and executing major strategic investments such as Asia’s largest integrated insulins facility in Malaysia for Biocon.
A technologist, Shreehas started his career in Research & Development and is an inventor on 61 patents, reflecting his commitment to advancing innovation.
He has represented India’s biopharmaceutical sector at leading global forums such as the Global Generics CEO Summit, the Festival of Biologics, and the U.S.-India Bioeconomy Workshop. Under his leadership, Biocon has worked closely with Indian policymakers on forward-looking frameworks such as the Production Linked Incentive (PLI) and the Promotion of Research and Innovation in Pharma MedTech (PRIP) schemes to prepare India for the future of life sciences.
Shreehas holds a Master’s degree in Bioprocess Technology from ICT (UDCT), University of Mumbai, and was conferred the Distinguished Alumnus Award (Professional) in 2020. He is also the winner of the ET Edge India’s Impactful CEO Award in 2025, the BW Pharma World Pharma Leadership Award along with the Times Now Most Promising Business Leaders of Asia Award in 2026.
